noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
BERKELEY, Calif., Dec. 27, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2017, at 10:00 am Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
